This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The interventions were dabigatran etexilate, warfarin (trial data), and usual care (real-world warfarin). The usual care consisted of prevention with warfarin or aspirin, or no treatment. This was examined using real-world data, with suboptimal therapeutic outcomes, according to those observed in clinical practice. The dose of dabigatran etexilate was 150mg for patients under 80 years old, or 110mg for patients aged 80 years or older.
Location/setting
Canada/primary care.
Methods

Analytical approach:
A decision-analytic Markov model was used to synthesise the evidence. Its structure was based on a developed model (Sorensen, et al. 2009 , see 'Other Publications of Related Interest' below for bibliographic details). It modelled a hypothetical cohort of adults with a mean age of 69 years, a diagnosis of atrial fibrillation, and at least one additional risk factor for stroke or embolism, or an impaired left ventricular ejection fraction, who were eligible for anticoagulation treatment. The time horizon was lifetime and the authors stated that a Canadian provincial health payer perspective was taken.
Effectiveness data:
The clinical data were mainly from published studies and one pivotal clinical trial; the Randomised Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial (Connolly, et al. 2009 (Connolly, et al. , 2010 , see 'Other Publications of Related Interest' below for bibliographic details). This trial compared the two doses of dabigatran etexilate with adjusted-dose warfarin, for 18,113 patients. The key clinical outcomes were disability measured on the modified Rankin Scale or the Glasgow Outcome Scale, mortality, quality of life, risk of future cardiac events, and changing treatment status. Other published studies, including a network meta-analysis of up to 20 trials, provided the efficacy data for warfarin and aspirin in trial and real-world settings. The efficacy for all three therapies was assumed to be constant over time. Discontinuation rates of 22% for warfarin and 30% for dabigatran etexilate were modelled.
Monetary benefit and utility valuations:
